Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target
Abstract High-risk sarcomas, such as metastatic and relapsed Ewing and CIC-rearranged sarcoma, still have a poor prognosis despite intensive therapeutic regimens. Precision medicine approaches offer hope, and ex vivo drug response profiling of patient-derived tumor cells emerges as a promising tool...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Portfolio
2025-08-01
|
| Серии: | Nature Communications |
| Online-ссылка: | https://doi.org/10.1038/s41467-025-62629-6 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|
